"Zidovudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
| Descriptor ID |
D015215
|
| MeSH Number(s) |
D03.383.742.680.705.950 D13.570.230.500.950 D13.570.230.855.950 D13.570.685.705.950
|
| Concept/Terms |
Zidovudine- Zidovudine
- Azidothymidine
- AZT Antiviral
- 3'-Azido-3'-deoxythymidine
- 3' Azido 3' deoxythymidine
- AZT (Antiviral)
- 3'-Azido-2',3'-Dideoxythymidine
- 3' Azido 2',3' Dideoxythymidine
- AZT, Antiviral
- Antiviral AZT
|
Below are MeSH descriptors whose meaning is more general than "Zidovudine".
Below are MeSH descriptors whose meaning is more specific than "Zidovudine".
This graph shows the total number of publications written about "Zidovudine" by people in this website by year, and whether "Zidovudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 2 | 4 |
| 1995 | 2 | 1 | 3 |
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 2000 | 4 | 0 | 4 |
| 2001 | 2 | 1 | 3 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Zidovudine" by people in Profiles.
-
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report. BMC Infect Dis. 2020 Jan 21; 20(1):68.
-
Increasing the anticancer activity of azidothymidine toward the breast cancer via rational design of magnetic drug carrier based on molecular imprinting technology. Mater Sci Eng C Mater Biol Appl. 2019 Oct; 103:109771.
-
Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana. J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug; 11(4):260-8.
-
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010 Jun 17; 362(24):2271-81.
-
Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics. 2009 Dec; 124(6):e1189-97.
-
Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy. Cardiovasc Toxicol. 2007; 7(4):255-63.
-
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007 Sep 12; 21(14):1899-907.
-
A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings. Pediatr Infect Dis J. 2006 Jan; 25(1):59-64.
-
Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol. 2003 Jul; 23(1):173-9.
-
Association of HIV-1 viral phenotype in the MT-2 assay with perinatal HIV transmission. J Acquir Immune Defic Syndr. 2002 May 01; 30(1):88-94.